Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
For the insurance industry, these developments present a serious challenge. Rising health risks translate to increased claims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback